Cargando…

Shexiang Baoxin Pills Could Alleviate Isoproterenol-Induced Heart Failure Probably through its Inhibition of CaV1.2 Calcium Channel Currents

Heart failure (HF) affects millions of patients in the world. Shexiang Baoxin Pills (SXB) are extensively applied to treat coronary artery diseases and HF in Chinese hospitals. However, there are still no explanations for why SXB protects against HF. To assess the protective role, we created the HF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jianwei, Yu, Juan, Qi, Jianyong, Zhang, Minzhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668454/ https://www.ncbi.nlm.nih.gov/pubmed/36405392 http://dx.doi.org/10.1155/2022/5498023

Ejemplares similares

Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro
por: Qi, Jianyong, et al.
Publicado: (2017)

Protective Effect of Shexiang Baoxin Pill on Myocardial Ischemia/Reperfusion Injury in Patients With STEMI
por: Qin, Haixia, et al.
Publicado: (2021)

Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow
por: Guo, Hongxin, et al.
Publicado: (2022)

A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases
por: Fang, Hai-Yang, et al.
Publicado: (2017)

Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

Shexiang Baoxin Pill for Acute Myocardial Infarction: Clinical Evidence and Molecular Mechanism of Antioxidative Stress
por: Guo, Jianbo, et al.
Publicado: (2021)

Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall
por: Lu, Li, et al.
Publicado: (2019)

Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats
por: Xiang, Li, et al.
Publicado: (2013)

Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria
por: Wei, Dan, et al.
Publicado: (2018)

Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
por: Dong, Taiwei, et al.
Publicado: (2018)

Shexiang Baoxin Pills for Coronary Heart Disease in Animal Models: Preclinical Evidence and Promoting Angiogenesis Mechanism
por: Zhang, Ke-Jian, et al.
Publicado: (2017)

Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy
por: Yang, Liu-qing, et al.
Publicado: (2019)

Efficacy of Shexiang Baoxin Pills for the treatment of unstable angina pectoris: Protocol of systemic review and meta-analysis
por: Chen, Huadong, et al.
Publicado: (2019)

Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases
por: Lu, Li, et al.
Publicado: (2018)

Antidepressant and anxiolytic effects of the proprietary Chinese medicine Shexiang Baoxin pill in mice with chronic unpredictable mild stress
por: Zhou, Xi-Dan, et al.
Publicado: (2018)

Shexiang Baoxin Pill, a Traditional Chinese Herbal Formula, Rescues the Cognitive Impairments in APP/PS1 Transgenic Mice
por: Hu, Wei-Hui, et al.
Publicado: (2020)

Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
por: Wei, Jingjing, et al.
Publicado: (2021)

Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials
por: Wei, Jingjing, et al.
Publicado: (2022)

Single-nucleus ribonucleic acid-sequencing and spatial transcriptomics reveal the cardioprotection of Shexiang Baoxin Pill (SBP) in mice with myocardial ischemia-reperfusion injury
por: Lin, Wenyong, et al.
Publicado: (2023)

Block Matching Pyramid Algorithm-Based Analysis on Efficacy of Shexiang Baoxin Pills Guided by Echocardiogram (ECG) on Patients with Angina Pectoris in Coronary Heart Disease
por: Gao, Junqing, et al.
Publicado: (2021)

Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial
por: Tian, Pan-pan, et al.
Publicado: (2018)

Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis
por: Wen, Jianxia, et al.
Publicado: (2018)

Shexiang Baoxin Pills Inhibited Proliferation and Migration of Human Coronary Artery Smooth Muscle Cells via PI3K/AKT/mTOR Pathway
por: Hua, Lei, et al.
Publicado: (2021)

Efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction: A single-center, double-blind, randomized controlled trial
por: Yang, Yan, et al.
Publicado: (2021)

Shexiang Baoxin Pill, a Formulated Chinese Herbal Mixture, Induces Neuronal Differentiation of PC12 Cells: A Signaling Triggered by Activation of Protein Kinase A
por: Xu, Miranda Li, et al.
Publicado: (2019)

Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial
por: Liu, Si-pei, et al.
Publicado: (2022)

Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
por: Zhou, Jingmin, et al.
Publicado: (2023)

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
por: Ge, Jun-Bo, et al.
Publicado: (2021)

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
por: Shi, Haiming, et al.
Publicado: (2022)

CaV1 and CaV2 calcium channels mediate the release of distinct pools of synaptic vesicles
por: Mueller, Brian D, et al.
Publicado: (2023)

Shexiang Baoxin Pill, a Proprietary Multi-Constituent Chinese Medicine, Prevents Locomotor and Cognitive Impairment Caused by Brain Ischemia and Reperfusion Injury in Rats: A Potential Therapy for Neuropsychiatric Sequelae of Stroke
por: Qin, Zong-Shi, et al.
Publicado: (2021)

Shexiang-Wulong Pills Attenuate Rheumatoid Arthritis by Alleviating Inflammation in a Mouse Model of Collagen-Induced Arthritis
por: Zhang, Zhihui, et al.
Publicado: (2019)

Synaptic vesicle capture by CaV2.2 calcium channels
por: Wong, Fiona K., et al.
Publicado: (2013)

Efficacy of Shexiang Tongxin Dropping Pills in a Swine Model of Coronary Slow Flow
por: Bai, Yupeng, et al.
Publicado: (2022)

Protective effects of Shexiang Tongxin Dropping Pill on pituitrin-induced acute myocardial ischemia in rats
por: Lin, Shan, et al.
Publicado: (2017)

Mechanistic contribution of CaV3.2 calcium channels to trigeminal neuralgia pathophysiology not clarified
por: Liedtke, Wolfgang
Publicado: (2022)

Shexiang Tongxin Dropping Pill Improves Peripheral Microvascular Blood Flow via Cystathionine-γ-Lyase
por: Zhang, Yanda, et al.
Publicado: (2019)

LC-MS-based metabolomics reveals the mechanism of anti-gouty arthritis effect of Wuwei Shexiang pill
por: Lang, Jirui, et al.
Publicado: (2023)

Interactions of Rabconnectin-3 with Cav2 calcium channels
por: Gandini, Maria A., et al.
Publicado: (2019)

Functional Exploration Of T-Type Calcium Channels (Cav3.2 And Cav3.3) And Their Sensitivity To Zinc
por: Hazzaz Abouamal, Tahar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3s5s93fq0n6ipojd4qqrnjmft6